Researchers report that patients with severe aortic stenosis who have a shorter life expectancy or place a low value on the risk of long-term valve degeneration may have more to gain from transfemoral transcatheter aortic valve implantation than surgical replacement.
Sacubitril–valsartan is cost-effective for the reduction of cardiovascular mortality and morbidity in patients with New York Heart Association class II to IV heart failure and reduced ejection fraction, US study findings indicate.
Less than a quarter of heart failure (HF) patients eligible for implantable cardioverter-defibrillator counselling actually receive it, with the rates even lower in women and ethnic minority patients, an observational analysis of the Get With The Guidelines-HF Program shows.
The glucagon-like peptide 1 agonist liraglutide does not improve clinical stability in patients recently hospitalised with advanced heart failure and reduced left ventricular ejection fraction, US researchers report.
Myocardial infarction survivors who have heart failure are more likely to develop cancer than their heart failure-free counterparts, indicates research published in the Journal of the American College of Cardiology.
The risk of readmission within 30 days of heart failure hospitalisation is reduced by a quarter for patients receiving sacubitril/valsartan compared with those receiving enalapril, an analysis of PARADIGM-HF trial data shows.
The American Heart Association has published a scientific statement that provides a comprehensive list of drugs, including complementary/alternative medications, that may cause or exacerbate heart failure.